Demographic/clinicopathological characteristics and prognosis of resectable Epstein-Barr virus-associated gastric cancer: a nested case-control study from an Eastern China.
환자-대조
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
400 patients at Ningbo No.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Compared to EBVnGC patients, EBVaGC patients showed a trend towards better DFS, although this did not reach statistical significance(p=0.061). [CONCLUSION] EBVaGC patients exhibit unique clinicopathological characteristics and may show a trend toward better prognosis compared with EBVnGC patients, although this difference did not reach statistical significance.
[BACKGROUND] Epstein-Barr virus-associated gastric cancer (EBVaGC) represents a distinct molecular subtype of gastric cancer (GC).
- p-value p=0.025
- p-value p=0.008
- HR 8.11
- 추적기간 34 months
APA
Gu L, Zhang Q, et al. (2025). Demographic/clinicopathological characteristics and prognosis of resectable Epstein-Barr virus-associated gastric cancer: a nested case-control study from an Eastern China.. Frontiers in oncology, 15, 1602091. https://doi.org/10.3389/fonc.2025.1602091
MLA
Gu L, et al.. "Demographic/clinicopathological characteristics and prognosis of resectable Epstein-Barr virus-associated gastric cancer: a nested case-control study from an Eastern China.." Frontiers in oncology, vol. 15, 2025, pp. 1602091.
PMID
41573653
Abstract
[BACKGROUND] Epstein-Barr virus-associated gastric cancer (EBVaGC) represents a distinct molecular subtype of gastric cancer (GC). This multicenter study aimed to investigate the clinicopathological characteristics and prognosis of resectable EBVaGC patients.
[METHODS] Data were prospectively collected and retrospectively analyzed from 1,400 patients at Ningbo No. 2 Hospital from January 2014 to December 2023 and 55 EBVaGC patients were identified. Additionally, 95 EBVaGC patients from two external cooperative centers were included. A 1:4 propensity score matching (PSM) analysis was performed between EBVaGC patients and EBV-negative gastric cancer (EBVnGC) patients. Median follow-up duration was 34 months.
[RESULTS] Among the 150 EBVaGC patients, the median age was 64, and 88.7% were male. Undifferentiated tumors were more common. During the follow-up, 121 EBVaGC patients did not experience recurrence. After PSM, there were 137 EBVaGC patients and 548 EBVnGC patients. In EBVaGC patients, elevated Carcinoembryonic Antigen (CEA) levels (HR = 8.11, p=0.025) and pathological tumor-node-metastasis (pTNM) stage III (HR = 19.57, p=0.008) were independent risk factors for overall survival (OS). For disease-free survival (DFS), elevated CEA levels (HR = 6.23, p=0.035) and pTNM stage III (HR = 18.51, p=0.007) were independent risk factors. There was no significant difference in OS between the two groups (p=0.204). Compared to EBVnGC patients, EBVaGC patients showed a trend towards better DFS, although this did not reach statistical significance(p=0.061).
[CONCLUSION] EBVaGC patients exhibit unique clinicopathological characteristics and may show a trend toward better prognosis compared with EBVnGC patients, although this difference did not reach statistical significance.
[METHODS] Data were prospectively collected and retrospectively analyzed from 1,400 patients at Ningbo No. 2 Hospital from January 2014 to December 2023 and 55 EBVaGC patients were identified. Additionally, 95 EBVaGC patients from two external cooperative centers were included. A 1:4 propensity score matching (PSM) analysis was performed between EBVaGC patients and EBV-negative gastric cancer (EBVnGC) patients. Median follow-up duration was 34 months.
[RESULTS] Among the 150 EBVaGC patients, the median age was 64, and 88.7% were male. Undifferentiated tumors were more common. During the follow-up, 121 EBVaGC patients did not experience recurrence. After PSM, there were 137 EBVaGC patients and 548 EBVnGC patients. In EBVaGC patients, elevated Carcinoembryonic Antigen (CEA) levels (HR = 8.11, p=0.025) and pathological tumor-node-metastasis (pTNM) stage III (HR = 19.57, p=0.008) were independent risk factors for overall survival (OS). For disease-free survival (DFS), elevated CEA levels (HR = 6.23, p=0.035) and pTNM stage III (HR = 18.51, p=0.007) were independent risk factors. There was no significant difference in OS between the two groups (p=0.204). Compared to EBVnGC patients, EBVaGC patients showed a trend towards better DFS, although this did not reach statistical significance(p=0.061).
[CONCLUSION] EBVaGC patients exhibit unique clinicopathological characteristics and may show a trend toward better prognosis compared with EBVnGC patients, although this difference did not reach statistical significance.
같은 제1저자의 인용 많은 논문 (5)
- Prevalence of Acute and Delayed Contrast Reactions With Multiple Exposures to Contrast-Enhanced Mammography-Experience From the TOCEM Trial.
- [Progress in microsurgical repair and reconstruction techniques and development of microsurgery in China].
- PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma.
- Clinicopathological features and prognosis of patients with resectable HAS/GAED: A multicenter nested case-control study from China.
- Subtractive thinking: A novel combined application of antihelix reconstruction and outer helix reconstruction to treat mild cases of type I to II conchal microtia.